US DHHS Guidelines with Australian commentary
Characteristics of the Fusion Inhibitor
Last Updated: October 25, 2018;
Last Reviewed: October 25, 2018
|Formulation||Dosing Recommendation||Serum Half-Life||Elimination||Adverse Eventsa|
||3.8 hours||Expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acids in the body pool||
|a Also see Table 15.
Key to Acronyms: BID = twice daily; HSR = hypersensitivity reaction; T-20 = enfuvirtide